ACE2 and infection: Animal studies showed that ACEIs and ARBs can upregulate ACE-2 [9], which raised concerns whether a higher availability of the entry receptor for SARS-CoV2 might result in increased infection rates and higher disease severity in patients with RAAS modulating drugs.